BELLSYSTEM24 : Supplementary Materials for Financial Results of the Fiscal Year Ended Feb. 2021

Supplementary Materials

for Financial Results of the Fiscal Year

Ended February 2021

(April 7, 2021)

Creating Better Communities through Communication

BELLSYSTEM24 Holdings, Inc.

1	© 2021 BELLSYSTEM24 Holdings, Inc.

FY ended Feb. 2021 Result Summary

Revenue increased sharply from the previous fiscal year. Impairment losses incurred in "Other Businesses" were absorbed and profitability was achieved.

		Revenue 135.7 billion yen	Same period YoY +7.2%
Consolidated		Operating profit 11.8 billion yen	Same period YoY +6.3%
Results
		Profit attributable to	7.2 billion yen	Same period YoY +3.5%
		owners of parent

Spot business related to COVID-19 made a significant contribution to growth.

Although the acquisition of new business was delayed throughout the year,

Continued Business also grew steadily.

2

FY ended Feb. 2021 Result Overview

Forecasts for both revenue and profit were achieved.

							(Unit: millions of yen)
			FY Feb. 2020	FY Feb. 2021			Forecast for	Progress rate
				Percentage of
			YOY change	FY Feb. 2021
					change
Revenue	126,663	135,735	+9,072	+7.2%	132,000	102.8%
	CRM Business	125,142	134,559	+9,417	+7.5%	－	－
		Continued Business	114,597	117,106	+2,509	+2.2%	－	－
		Spot Business	10,545	17,453	+6,908	+65.5%	－	－
	Other Businesses	1,521	1,176	-345	-22.7%	－	－
Operating Profit	11,105	11,799	+694	+6.3%	11,500	102.6%
	CRM Business	10,978	12,367	+1,389	+12.7%	－	－
	Other Businesses	127	-568	-695	-547.2%	－	－
Profit Attributable to	7,006	7,252	+246	+3.5%	7,200	100.7%
Owners of Parent

* The operating profit of "Other Businesses" for FY Feb. 2021 includes impairment losses of 845 million yen relating to POCKE,INC.

3

Trends in Revenue and Operating Profit (Past 5 Years)

(Unit: billions of yen)

Revenue		+4.7%		+4.6%		+7.2%
+6.2%				135.74
		121.11		126.66
	115.62
108.92
			CAGR +5.7%

FY ended Feb. 2017 FY ended Feb. 2018	FY ended Feb. 2019	FY ended Feb. 2020	FY ended Feb. 2021
(FY2016)	(FY2017)	(FY2018)	(FY2019)		(FY2020)
					* Excluding the effect of restructuring the					* Excluding the effect of recognizing impairment
Operating Profit and Operating Profit Ratio					losses in "Other Businesses," operating profit is
the operating profit ratio is 8.4%.
					pharmaceutical business, operating profit is 10.22 and		12.66 and the operating profit ratio is 9.3%.
							+29.4%			+6.3%
										11.80
	+14.1%			-7.9%			11.11
		9.32
		8.58
8.17

CAGR +9.6%

• Figures in parentheses indicate operating profit ratio.

(7.5%)	(8.1%)	(7.1%)	(8.8%)	(8.7%)
FY ended Feb. 2017	FY ended Feb. 2018	FY ended Feb. 2019	FY ended Feb. 2020	FY ended Feb. 2021
(FY2016)	(FY2017)	(FY2018)	(FY2019)	(FY2020)
		4

Trends in Revenue and Operating Profit (Quarterly)

Revenue													(Unit: billions of yen)
												32.20	32.40		32.68	34.19	35.27	33.60
										31.07	30.84	31.23
					29.48	29.00	30.15	29.91	29.97
28.56	28.58

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

FY Feb. 2018

FY Feb. 2019

FY Feb. 2020

FY Feb. 2021

Operating Profit and Operating Profit Ratio

* Excluding the effect of restructuring the pharmaceutical business, operating profit is 2.48 and the operating profit ratio is 8.0%.

• Excluding the effect of recognizing impairment losses in "Other Businesses," operating profit is 2.51 and the operating profit ratio is 7.5%.
  3.57 3.53

		2.69		2.79	2.56			2.92	2.96	2.99		3.05
2.25	2.14		2.24		2.40
							2.24
															1.65
							0.84
(7.9%)	(7.5%)	(9.1%)	(7.7%)	(9.2%)	(8.6%)	(8.0%)	(2.7%)	(9.5%)	(9.2%)	(9.2%)	(7.2%)	(9.3%)	(10.4%)	(10.0%)		(4.9%)

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

1Q

2Q

3Q

4Q

FY Feb. 2018

FY Feb. 2019

FY Feb. 2021

FY Feb. 2021

* Figures in

parentheses

indicate operating

5

profit ratio.